Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.

ABSTRACT: Ovarian cancer (OC), one of the most common malignancies of the female reproductive system, is characterized by high incidence and poor prognosis. Tumor mutation burden (TMB), as an important biomarker that can represent the degree of tumor mutation, is emerging as a key indicator for predicting the efficacy of tumor immunotherapy. In our study, the gene expression profiles of OC were downloaded from TCGA and GEO databases. Subsequently, we analyzed the prognostic value of TMB in OC and found that a higher TMB score was significantly associated with a better prognosis (p = 0.004). According to the median score of TMB, 9 key TMB related immune prognostic genes were selected by LASSO regression for constructing a TMB associated immune risk score (TMB-IRS) signature, which can effectiv

SUBMITTER: Cui M 

PROVIDER: S-EPMC8787320 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature